UroGen Pharma Ltd
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder… Read more
UroGen Pharma Ltd (URGN) - Total Liabilities
Latest total liabilities as of December 2025: $305.93 Million USD
Based on the latest financial reports, UroGen Pharma Ltd (URGN) has total liabilities worth $305.93 Million USD as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
UroGen Pharma Ltd - Total Liabilities Trend (2013–2025)
This chart illustrates how UroGen Pharma Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
UroGen Pharma Ltd Competitors by Total Liabilities
The table below lists competitors of UroGen Pharma Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
JSW Holdings Limited
NSE:JSWHL
|
India | ₹42.83 Billion |
|
Legend Holdings Corporation
PINK:LGNRF
|
USA | $623.79 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥82.76 Million |
|
Gujarat Gas Limited
NSE:GUJGASLTD
|
India | ₹46.72 Billion |
|
Uniqure NV
NASDAQ:QURE
|
USA | $659.64 Million |
|
Esquire Financial Holdings Inc
NASDAQ:ESQ
|
USA | $2.08 Billion |
|
CytomX Therapeutics Inc
NASDAQ:CTMX
|
USA | $50.87 Million |
|
Astria Therapeutics Inc
NASDAQ:ATXS
|
USA | $38.61 Million |
Liability Composition Analysis (2013–2025)
This chart breaks down UroGen Pharma Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.01 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.90 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.53 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how UroGen Pharma Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for UroGen Pharma Ltd (2013–2025)
The table below shows the annual total liabilities of UroGen Pharma Ltd from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $305.93 Million | +3.88% |
| 2024-12-31 | $294.51 Million | +20.94% |
| 2023-12-31 | $243.52 Million | +8.24% |
| 2022-12-31 | $224.98 Million | +102.08% |
| 2021-12-31 | $111.33 Million | +334.05% |
| 2020-12-31 | $25.65 Million | +16.14% |
| 2019-12-31 | $22.09 Million | +64.03% |
| 2018-12-31 | $13.46 Million | +91.40% |
| 2017-12-31 | $7.04 Million | +4.24% |
| 2016-12-31 | $6.75 Million | +201.70% |
| 2015-12-31 | $2.24 Million | +151.07% |
| 2014-12-31 | $891.00K | +84.09% |
| 2013-12-31 | $484.00K | -- |